Business Description
Daehan New Pharm Co Ltd
ISIN : KR7054670005
Compare
Compare
Traded in other countries / regions
054670.Korea IPO Date
2002-02-26Description
Daehan New Pharm Co Ltd is a South Korea based company operating in the pharmaceutical sector. It is engaged in producing pharmaceutical products, animal health and nutrition, and bio products. The pharmaceutical products are tertan tab, amloc tab, tarocin SR tab, NP star tab and others. The animal health and nutrition products are starvac, pigcoc for calves, ocean doctor, and others. The bio range of the products by the group are CELRENA serum-free, BMPro serum-free, BMPro-V serum-free, ALyS505NK-EX serum-free and others.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.76 | |||||
| Equity-to-Asset | 0.63 | |||||
| Debt-to-Equity | 0.3 | |||||
| Debt-to-EBITDA | 1.39 | |||||
| Interest Coverage | 10.16 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 3.01 | |||||
| Beneish M-Score | -2.65 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 11 | |||||
| 3-Year FCF Growth Rate | -12.6 | |||||
| 3-Year Book Growth Rate | 22.7 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 53.99 | |||||
| 9-Day RSI | 54.63 | |||||
| 14-Day RSI | 52.13 | |||||
| 6-1 Month Momentum % | -14.22 | |||||
| 12-1 Month Momentum % | -17.87 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.57 | |||||
| Quick Ratio | 1.06 | |||||
| Cash Ratio | 0.41 | |||||
| Days Inventory | 108.75 | |||||
| Days Sales Outstanding | 63.74 | |||||
| Days Payable | 39.65 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.24 | |||||
| Dividend Payout Ratio | 0.13 | |||||
| Forward Dividend Yield % | 1.24 | |||||
| 5-Year Yield-on-Cost % | 1.23 | |||||
| Shareholder Yield % | 0.75 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 46.74 | |||||
| Operating Margin % | 8.87 | |||||
| Net Margin % | 6.64 | |||||
| FCF Margin % | 2.94 | |||||
| ROE % | 11.79 | |||||
| ROA % | 7.39 | |||||
| ROIC % | 8.81 | |||||
| ROC (Joel Greenblatt) % | 23.05 | |||||
| ROCE % | 18.32 | |||||
| Years of Profitability over Past 10-Year | 7 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 8.51 | |||||
| PE Ratio without NRI | 10.76 | |||||
| Shiller PE Ratio | 24.96 | |||||
| Price-to-Owner-Earnings | 10.23 | |||||
| PS Ratio | 0.57 | |||||
| PB Ratio | 0.96 | |||||
| Price-to-Tangible-Book | 0.97 | |||||
| Price-to-Free-Cash-Flow | 19.27 | |||||
| Price-to-Operating-Cash-Flow | 6.78 | |||||
| EV-to-EBIT | 5.6 | |||||
| EV-to-EBITDA | 4.79 | |||||
| EV-to-Revenue | 0.61 | |||||
| EV-to-FCF | 20.74 | |||||
| Price-to-Projected-FCF | 0.54 | |||||
| Price-to-Median-PS-Value | 0.44 | |||||
| Price-to-Graham-Number | 0.68 | |||||
| Price-to-Net-Current-Asset-Value | 3.62 | |||||
| Earnings Yield (Greenblatt) % | 17.87 | |||||
| FCF Yield % | 5.19 | |||||
| Forward Rate of Return (Yacktman) % | 26.89 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Daehan New Pharm Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil â‚©) | 200,963.108 | ||
| EPS (TTM) (â‚©) | 951 | ||
| Beta | 0.78 | ||
| Volatility % | 16.65 | ||
| 14-Day RSI | 52.13 | ||
| 14-Day ATR (â‚©) | 144.413749 | ||
| 20-Day SMA (â‚©) | 8017 | ||
| 12-1 Month Momentum % | -17.87 | ||
| 52-Week Range (â‚©) | 7670 - 10410 | ||
| Shares Outstanding (Mil) | 14.04 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Daehan New Pharm Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Daehan New Pharm Co Ltd Stock Events
| Event | Date | Price(â‚©) | ||
|---|---|---|---|---|
| No Event Data | ||||
Daehan New Pharm Co Ltd Frequently Asked Questions
What is Daehan New Pharm Co Ltd(XKRX:054670)'s stock price today?
The current price of XKRX:054670 is â‚©8090.00. The 52 week high of XKRX:054670 is â‚©10410.00 and 52 week low is â‚©7670.00.
When is next earnings date of Daehan New Pharm Co Ltd(XKRX:054670)?
The next earnings date of Daehan New Pharm Co Ltd(XKRX:054670) is .
Does Daehan New Pharm Co Ltd(XKRX:054670) pay dividends? If so, how much?
The Dividend Yield %  of Daehan New Pharm Co Ltd(XKRX:054670) is 1.24% (As of Today), Highest Dividend Payout Ratio of Daehan New Pharm Co Ltd(XKRX:054670) was 0.13. The lowest was 0.06. And the median was 0.07. The  Forward Dividend Yield % of Daehan New Pharm Co Ltd(XKRX:054670) is 1.24%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers